Texas House Bill HB2767

Texas 2023 - 88th Regular

• Filed: 2/23/23
• Out of House Committee: 3/30/23
• Voted on by House: 5/6/23

Caption

Relating to the sharing of controlled substance prescription monitoring information between the Texas State Board of Pharmacy and the Health and Human Services Commission for the state Medicaid program.

Impact

The impact of HB 2767 on state law is significant, as it will amend the Health and Safety Code to grant Medicaid authority to access sensitive prescription data. This move is critical for aligning state regulations with federal mandates, hence improving oversight of prescription drug use among Medicaid recipients. The bill seeks to facilitate the accurate completion of reporting requirements which were previously challenging under the existing law.

Summary

House Bill 2767 pertains to the collaboration between the Texas State Board of Pharmacy and the Health and Human Services Commission regarding the sharing of controlled substance prescription monitoring information. The bill allows the Health and Human Services Commission (HHS) to access data from the Texas Prescription Monitoring Program (PMP) to fulfill federal requirements related to the Medicaid program. Prior to this legislation, state law restricted Medicaid's access to this essential data, thus hindering its ability to identify issues such as prescription fraud and abuse effectively.

Sentiment

The general sentiment surrounding HB 2767 appears to be positive, especially among supporters from the health sector who emphasize the necessity of effective data sharing to combat prescription drug misuse. Legislative discussions pointed towards an understanding that the bill is a clean-up act intended to streamline essential processes. However, there was no significant opposition noted in the documentation, which could indicate broad agreement on the need for enhanced monitoring capability within Medicaid.

Contention

While HB 2767 is largely viewed as a necessary measure for improving prescription oversight, it does raise some concerns regarding potential privacy implications associated with increased data access by Medicaid. Stakeholders in the health sector may debate the balance between effective fraud prevention and patient privacy rights. Nonetheless, these concerns did not seem to trigger notable contention in legislative discussions or voting outcomes, where the bill passed overwhelmingly.